Despite Supreme Court Ruling, Foreign Sales Don’t Affect US Patent Rights 29/03/2016 by Steven Seidenberg for Intellectual Property Watch Leave a Comment The controversial ruling was perhaps to be expected. The Federal Circuit Court of Appeals doggedly hewed to its existing interpretation of patent law. Unfortunately, the court’s decision in Lexmark International v Impression Products conflicts with recent Supreme Court jurisprudence, according to many experts – thus leaving unresolved some important questions about how much control patentees can maintain over their patented products.
Biotherapeutic Medicines, A New Frontier, Face Regulatory Issues 24/03/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment Biotherapeutic medicines, engineered by living organisms, have opened a promising path to treat major diseases. Near copies of these medicines, called biosimilars, are slowly coming to market, as the originator products become free of intellectual property rights or data protection. However, some regulatory issues are left to be addressed, in particular in developing countries, according to the pharmaceutical industry and the World Health Organization. For patients, information on those products and their affordability are key, said a patient group representative.
Geographical Indications In The TTIP: Faites Vos Jeux 23/03/2016 by Monika Ermert for Intellectual Property Watch Leave a Comment Ever heard of Törkölypálinka? It is a Hungarian grape marc spirit and one of approximately 200 geographical origins listed by the European Commission negotiators of the Transatlantic Trade and Investment Partnership (TTIP). In their newly published proposals, the EU negotiators laid out their ideas on GI protection in the deal, and point to an earlier EU-US agreement with regard to GI protection of wines and spirits. But they also acknowledge the need for considerable bridging between the two systems. GI protection is expected to be one of the highly controversial issues in the “end game” of TTIP.
UN High-Level Panel: Ideas For Change To Global Health And IP System Proliferate 19/03/2016 by William New and Catherine Saez, Intellectual Property Watch 3 Comments Public health advocates, academics, patients, governments and others this week presented further ideas to the United Nations Secretary-General’s High-Level Panel on Access to Medicines on ways to break the longstanding pattern of expensive medical products around the world as a way to pay for research and development.
Asian Voices On Access to Medicines: Scrap TRIPS, Voluntary Licences Not Working, FTA Threats 18/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments Speakers from Asian civil society provided recommendations to the public hearing of the United Nations Secretary General’s High-Level Panel on Access to Medicines held yesterday. They underlined the unaffordability of medicines in their countries, the inefficiency of current mechanisms such as voluntary licensing, and the pressure applied by pharmaceutical companies and the United States and Europe to prevent the use of compulsory licences. One speaker warned against the expert advice given by the World Intellectual Property Organization to least-developed countries, while others pointed to stringent intellectual property measures in free-trade agreements.
US Congress Hearing All Positive On IANA Transition Process 17/03/2016 by Monika Ermert for Intellectual Property Watch 2 Comments Witnesses testifying at the United States House Communications and Technology Subcommittee today unanimously reported success of the multistakeholder preparations for the transition of oversight over the Internet Assigned Numbers Authority (IANA) from the US government to the multistakeholder internet community.
Another Big Turnout For Second Public Dialogue Of UN High-Level Panel On Medicines Access 17/03/2016 by William New and Catherine Saez, Intellectual Property Watch Leave a Comment Today in Johannesburg, South Africa, the second of two public dialogues was held by the United Nations Secretary General’s High-Level Panel on Access to Medicines, drawing another packed room and many ideas, experiences and suggestions for solutions.
Ukraine To Amend Customs Code, Ratify Amendments To TRIPS 16/03/2016 by Jaroslaw Adamowski for Intellectual Property Watch 1 Comment The Ukrainian Parliament is currently drafting an amended Customs Code to introduce a number of changes to the country’s intellectual property legislation. Moreover, in mid-March, local lawmakers authorised Ukraine’s President Petro Poroshenko to ratify the protocol amending the TRIPS agreement which enables increased exports of pharmaceuticals produced under compulsory licences to countries which are not capable of manufacturing them locally.
China’s Pharmaceutical Sector And The IP Puzzle 15/03/2016 by Intellectual Property Watch Leave a Comment Despite impressive growth, the pharmaceutical sector in China still relies on generic drug production since the majority of domestic companies cannot compete with country-based foreign corporations. Currently, following WTO pressure to oblige China to comply with IP regulations, more and more patented drugs are entering the market. Unfortunately, in spite of a newly introduced IP friendly bill, a puzzling situation persists, writes Pietro Dionisio.
High-Level UN Initiative On Global Public Health Gap Holds Landmark Hearing 11/03/2016 by Catherine Saez and William New, Intellectual Property Watch 4 Comments An initiative of the United Nations secretary general yesterday gathered what could be described as an assembly of many of the world’s best thinkers and practitioners on public health and intellectual property rights. Industry, activists, academics, international organisations, and possibly some governments poured out their views for nearly seven hours – at times coming to tears and tension – shepherded by an astute moderator, as they responded to the call to take a longstanding debate on medicines access and high prices to a breakthrough.